PMID- 35421298
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20220418
IS  - 1210-7778 (Print)
IS  - 1210-7778 (Linking)
VI  - 30
IP  - 1
DP  - 2022 Mar
TI  - Real-life experience in the effectiveness, impact on quality of life and safety 
      of dupilumab treatment in patients with moderate to severe atopic dermatitis in 
      the Czech Republic.
PG  - 46-50
LID - 10.21101/cejph.a6885 [doi]
AB  - OBJECTIVES: The aim of the study was to assess the effectiveness and safety of 
      dupilumab therapy in patients with moderate-to-severe atopic dermatitis (AD) in a 
      real-life Czech bicentric cohort. METHODS: We retrospectively analysed 50 
      patients with moderate-to-severe AD treated with dupilumab in two centres in the 
      Czech Republic. Baseline characteristics, the Eczema Area and Severity Index 
      (EASI) score and Dermatology Life Quality Index (DLQI) were collected at baseline 
      and each 3 following months. The proportion of patients achieving EASI50, EASI75, 
      EASI90 and EASI100 were analysed. Levels of immunoglobulin E (IgE) were collected 
      before and after 6 and 12 months of therapy. Adverse events were recorded as 
      well. RESULTS: Thirty-two men and 18 women with mean body mass index (BMI) of 
      25.7 were enrolled in our analysis. The mean age of the patients was 37.6 years 
      and the mean time from diagnosis until the initiation of dupilumab therapy was 
      35.0 years. After 4 months, EASI75 was achieved by 75.7%, out of which 40.5% 
      achieved EASI90 and 10.8% achieved complete clearance. Improvement continued with 
      time, and the proportion of patients with EASI90 increased to 71.4% at the 6th 
      month and at the 12th month of therapy the EASI90 was 65.2%. EASI100 was achieved 
      by 14.3% and 13.0% at the 6th and 12th month, respectively. A marked reduction 
      was observed in the DLQI and also in IgE levels. EASI responses were independent 
      of BMI. No new safety issues were identified. Adverse events were experienced by 
      44% (22/50) of the patients and they were all mild in intensity. Conjunctivitis 
      and herpes simplex virus infection were the most common adverse events. 
      CONCLUSION: Our results confirmed the effectiveness and safety of dupilumab in a 
      real-life setting in adult patients with moderate-to-severe AD in the Czech 
      Republic. Dupilumab was well-tolerated and resulted in a significant clinical 
      improvement in combination with improvement of quality of life.
FAU - Tanczosova, Milena
AU  - Tanczosova M
AD  - Department of Dermatovenereology, Charles University, Third Faculty of Medicine 
      and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
FAU - Kojanova, Martina
AU  - Kojanova M
AD  - Department of Dermatovenereology, First Faculty of Medicine, Charles University 
      and General University Hospital, Prague, Czech Republic.
FAU - Arenbergerova, Monika
AU  - Arenbergerova M
AD  - Department of Dermatovenereology, Charles University, Third Faculty of Medicine 
      and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
FAU - Arenberger, Petr
AU  - Arenberger P
AD  - Department of Dermatovenereology, Charles University, Third Faculty of Medicine 
      and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
FAU - Dolezal, Tomas
AU  - Dolezal T
AD  - Value Outcomes, Prague, Czech Republic.
FAU - Strosova, Daniela
AU  - Strosova D
AD  - Value Outcomes, Prague, Czech Republic.
FAU - Fialova, Jorga
AU  - Fialova J
AD  - Department of Dermatovenereology, First Faculty of Medicine, Charles University 
      and General University Hospital, Prague, Czech Republic.
FAU - Gkalpakiotis, Spyridon
AU  - Gkalpakiotis S
AD  - Department of Dermatovenereology, Charles University, Third Faculty of Medicine 
      and University Hospital of Kralovske Vinohrady, Prague, Czech Republic.
LA  - eng
PT  - Journal Article
PL  - Czech Republic
TA  - Cent Eur J Public Health
JT  - Central European journal of public health
JID - 9417324
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized
MH  - Czech Republic/epidemiology
MH  - *Dermatitis, Atopic/diagnosis/drug therapy
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/therapeutic use
MH  - Male
MH  - *Quality of Life
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - atopic dermatitis
OT  - biological treatment
OT  - conjunctivitis
OT  - dupilumab
OT  - real-life
EDAT- 2022/04/15 06:00
MHDA- 2022/04/19 06:00
CRDT- 2022/04/14 18:43
PHST- 2021/04/20 00:00 [received]
PHST- 2022/01/12 00:00 [accepted]
PHST- 2022/04/14 18:43 [entrez]
PHST- 2022/04/15 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
AID - 10.21101/cejph.a6885 [doi]
PST - ppublish
SO  - Cent Eur J Public Health. 2022 Mar;30(1):46-50. doi: 10.21101/cejph.a6885.